These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6213574)

  • 1. Kinetic studies of the immunopharmacologic effects of NPT 15392 in mice.
    Florentin I; Taylor E; Davigny M; Mathé G; Hadden JW
    Int J Immunopharmacol; 1982; 4(3):225-33. PubMed ID: 6213574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of NPT 15392 in vitro on human leukocyte functions.
    Hadden JW; Hadden EM; Spira T; Settineri R; Simon L; Giner-Sorolla A
    Int J Immunopharmacol; 1982; 4(3):235-42. PubMed ID: 6179891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoenhancing activity of NPT 15392: a potential immune response modifier.
    Merluzzi VJ; Walker MM; Williams N; Susskind B; Hadden JW; Faanes RB
    Int J Immunopharmacol; 1982; 4(3):219-24. PubMed ID: 7049973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo immunomodulating properties of two synthetic agents: azimexon and tuftsin.
    Florentin I; Schulz J; Bruley-Rosset M; Kiger N; Martinez J; Mathé G
    Recent Results Cancer Res; 1980; 75():153-61. PubMed ID: 6894500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro effects of two immunopotentiators, Isoprinosine and NPT 15392, on murine T-cell differentiation and function.
    Ikehara S; Hadden JW; Good RA; Lunzer DG; Pahwa RN
    Thymus; 1981 Aug; 3(2):87-95. PubMed ID: 6170135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
    Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
    Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of immunomodulating action of TI-31 on antibody response in mice.
    Komoriya K; Nagata I; Takeshita T; Yamamoto I
    J Pharmacobiodyn; 1991 Aug; 14(8):443-7. PubMed ID: 1837801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic analysis of the immunopotentiating effect of the hypoxanthine analogue, NPT-15392, on the interleukin-2 production potential of human lymphocytes.
    Donnelly RP; Tsang KY; Bishop LR; Fudenberg HH
    Int J Immunopharmacol; 1986; 8(6):621-7. PubMed ID: 3491799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunopotentiating effects of the adjuvants SGP and Quil A. I. Antibody responses to T-dependent and T-independent antigens.
    Flebbe LM; Braley-Mullen H
    Cell Immunol; 1986 Apr; 99(1):119-27. PubMed ID: 3489557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The selectivity of isoprinosine, NPT 15392, avridine and cyclophosphamide on multiple immune responses in rats.
    Exon JH; Henningsen GM; Koller LD; Talcott PA
    Int J Immunopharmacol; 1986; 8(1):53-62. PubMed ID: 2420733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depression of natural killer activity and mitogen responsiveness in mice treated with pristane.
    Freund YR; Blair PB
    J Immunol; 1982 Dec; 129(6):2826-30. PubMed ID: 7142708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of immunological depression in mice exposed to normobaric oxygen.
    Levacher-Place M; Gougerot-Pocidalo MA; Rouveix B; Kraus L; Pocidalo JJ
    Clin Exp Immunol; 1983 Nov; 54(2):580-6. PubMed ID: 6360440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition by NPT 15392 of lymphocyte cyclic GMP phosphodiesterase.
    Coffey RG; Hartley L; Polson JB; Krzanowski JJ; Hadden JW
    Biochem Pharmacol; 1984 Nov; 33(21):3411-7. PubMed ID: 6093811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of murine NK cell activity generation by ST 789.
    Riccardi C; Migliorati G
    Thymus; 1992; 19 Suppl 1():S109-12. PubMed ID: 1585416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of in vivo treatments with cyclosporin-A on mouse cell-mediated immune responses.
    Alberti S; Boraschi D; Luini W; Tagliabue A
    Int J Immunopharmacol; 1981; 3(4):357-64. PubMed ID: 6977503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunopotentiation by SGP and Quil A. II. Identification of responding cell populations.
    Flebbe LM; Braley-Mullen H
    Cell Immunol; 1986 Apr; 99(1):128-39. PubMed ID: 3489558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of L-alanosine on immune response.
    Mistrello G; Bassi L
    J Immunopharmacol; 1984; 6(1-2):25-41. PubMed ID: 6470495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FCE20696, a new synthetic immunomodulator: immunopharmacological profile.
    Isetta AM; Fornasiero MC; Ferrari M; Trizio D
    Agents Actions; 1989 Nov; 28(3-4):283-9. PubMed ID: 2531974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotoxicity of the semiconductor gallium arsenide in female B6C3F1 mice.
    Sikorski EE; McCay JA; White KL; Bradley SG; Munson AE
    Fundam Appl Toxicol; 1989 Nov; 13(4):843-58. PubMed ID: 2695379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-Acetyl-D-glucosamine-coated polyamidoamine dendrimer modulates antibody formation via natural killer cell activation.
    Hulikova K; Benson V; Svoboda J; Sima P; Fiserova A
    Int Immunopharmacol; 2009 Jun; 9(6):792-9. PubMed ID: 19303462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.